Table 1. DCP antagonizes Sorafenib-mediated inhibition of HCC tumor growth HLE xenograft-bearing nude mice.

Groups	Number of mice (n)	Body weight (g)a (initial/21 days)	Tumor weightb (g, mean ± SD)	Tumor growth inhibition (%)
Vehicle	6	18.3 ± 1.1/21.2 ± 1.2	1.03 ± 0.26	-
Sorafenib 25 mg/kg	6	18.5 ± 1.4/20.5 ± 1.6	0.52 ± 0.22**	49.3
DCP 40 μg/kg	6	18.3 ± 1.3/21.8 ± 1.4	1.29 ± 0.29*	−25.2
Sorafenib + DCP	6	18.6 ± 0.9/20.4 ± 1.7	0.98 ± 0.21	4.8

Established xenografts were treated with Sorafenib by gavage, DCP by intravenous injection or Sorafenib plus DCP. All treatments were performed five times per week for three weeks in total.

^aBody weight was measured as indicated over time.

^bTumors were measured after mice were sacrificed.

^*p < 0.05

^**p < 0.01 vs. the vehicle control.